These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 1009681)

  • 1. Immune complexes and complement hypercatabolism in patients with leprosy.
    Bjorvatn B; Barnetson RS; Kronvall G; Zubler RH; Lambert PH
    Clin Exp Immunol; 1976 Dec; 26(3):388-96. PubMed ID: 1009681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum immune complexes in erythema nodosum leprosum reactions of leprosy.
    Rao TD; Rao PR
    Indian J Lepr; 1988 Apr; 60(2):189-95. PubMed ID: 3142953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solubilization of preformed immune complexes in sera of patients with type 1 and type 2 lepra reactions.
    Chakrabarty AK; Kashyap A; Sehgal VN; Saha K
    Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):559-65. PubMed ID: 3221112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immune complexes and complement in leprosy (author's transl)].
    Geniteau M; Adam C; Verroust P; Pasticier A; Saimot G; Coulaud JP; Languillon J
    Nouv Presse Med; 1981 Dec; 10(45):3697-700. PubMed ID: 7322902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL).
    Saha K; Chakraborty AK; Sharma V; Sehgal VN
    Lepr Rev; 1982 Dec; 53(4):253-60. PubMed ID: 6984124
    [No Abstract]   [Full Text] [Related]  

  • 6. Activation of complement by circulating immune complexes isolated from leprosy patients.
    Tyagi P; Ramanathan VD; Girdhar BK; Katoch K; Bhatia AS; Sengupta U
    Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):31-8. PubMed ID: 2319186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune complexes in leprosy patients from an endemic and a nonendemic area and a longitudinal study of the relationship between complement breakdown products and the clinical activity of erythema nodosum leprosum.
    Valentijn RM; Faber WR; Lai A Fat RF; Chan Pin Jie JC; Daha MR; van Es LA
    Clin Immunol Immunopathol; 1982 Feb; 22(2):194-202. PubMed ID: 6980747
    [No Abstract]   [Full Text] [Related]  

  • 8. Polyethylene glycol precipitates in serum during and after erythema nodosum leprosum--study of their composition and anticomplementary activity.
    Saha K; Chakrabarty AK; Sharma VK; Sehgal VN
    Int J Lepr Other Mycobact Dis; 1984 Mar; 52(1):44-8. PubMed ID: 6538557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exacerbation reactions in hyperactive lepromatous leprosy.
    Ridley DS; Ridley MJ
    Int J Lepr Other Mycobact Dis; 1984 Sep; 52(3):384-94. PubMed ID: 6541206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity.
    Nydegger UE; Zubler RH; Gabay R; Joliat G; Karagevrekis CH; Lambert PH; Miescher PA
    J Clin Invest; 1977 May; 59(5):862-8. PubMed ID: 853126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive evaluation of complement components in the course of type I (Lepra) and type II (ENL) reactions.
    Sehgal VN; Sharma V; Sharma VK
    Int J Dermatol; 1989; 28(1):32-5. PubMed ID: 2783924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of the C3 component of complement in sera of hanseniasis patients.
    Kliemann TA; Martinez EL; Irulegui I; de Souza ZW; Cavalcanti ZM
    Hansenol Int; 1983 Jun; 8(1):5-8. PubMed ID: 6432691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.
    Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN
    Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced complement-mediated immune complex solubilization in leprosy patients.
    Ramanathan VD; Sharma P; Ramu G; Sengupta U
    Clin Exp Immunol; 1985 Jun; 60(3):553-8. PubMed ID: 3874729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ and in vitro characterization of the cellular immune response in erythema nodosum leprosum.
    Modlin RL; Mehra V; Jordan R; Bloom BR; Rea TH
    J Immunol; 1986 Feb; 136(3):883-6. PubMed ID: 2416837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythema nodosum leprosum (ENL) in histoid leprosy.
    Sehgal VN; Gautam RK; Srivastava G; Koranne RV; Beohar PC
    Indian J Lepr; 1985; 57(2):346-9. PubMed ID: 4078360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ConA-induced suppressor cells in lepromatous leprosy patients during and after erythema nodosum leprosum.
    Sasiain MC; Ruibal Ares B; Baliña LM; Valdez R; Bachmann AE
    Int J Lepr Other Mycobact Dis; 1983 Sep; 51(3):321-7. PubMed ID: 6227570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards understanding the pathology of erythema nodosum leprosum.
    Kahawita IP; Lockwood DN
    Trans R Soc Trop Med Hyg; 2008 Apr; 102(4):329-37. PubMed ID: 18313706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum lymphocytotoxic activity in leprosy.
    Rasheed FN; Locniskar M; McCloskey DJ; Hasan RS; Chiang TJ; Rose P; de Soldenhoff R; Festenstein H; McAdam KP
    Clin Exp Immunol; 1989 Jun; 76(3):391-7. PubMed ID: 2752595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of serum fibrinolytic activity in erythema nodosum leprosum (ENL).
    Jain VK; Verma KC; Aggarwal SS
    Lepr India; 1983 Jan; 55(1):95-9. PubMed ID: 6876766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.